6-chloro-2-(pyrrolidin-1-yl)-7-(trimethylsilyl)pyrazolo[1,5-a]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 6-chloro-2-(pyrrolidin-1-yl)-7-(trimethylsilyl)pyrazolo[1,5-a]pyridine
• 英文别名: 6-Chloro-2-(pyrrolidin-1-yl)-7-(trimethylsilyl)pyrazolo[1,5-a]pyridine；(6-chloro-2-pyrrolidin-1-ylpyrazolo[1,5-a]pyridin-7-yl)-trimethylsilane
• 化学式: C₁₄H₂₀ClN₃Si
• 分子量: 293.871
• InChiKey: WDGIODMSVVCNSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.13
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-chloro-2-(pyrrolidin-1-yl)-7-(trimethylsilyl)pyrazolo[1,5-a]pyridine 在 三乙基硅烷 、 N-溴代丁二酰亚胺(NBS) 、 正丁基锂 、 四丁基氟化铵 、 三氟乙酸 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 乙腈 为溶剂， 反应 4.5h， 生成 methyl 6-[[6-chloro-2-(pyrrolidin-1-yl)pyrazolo[1,5-a]pyridin-3-yl]methyl]pyridine-2-carboxylate
  参考文献：
  名称：

  Discovery of novel pyrazolo[1,5-a]pyridine-based EP1 receptor antagonists by scaffold hopping: Design, synthesis, and structure-activity relationships

  摘要：

  A scaffold-hopping strategy towards a new pyrazolo[1,5-a]pyridine based core using molecular hybridization of two structurally distinct EP1 antagonists, followed by structure-activity relationship guided optimization, resulted in the identification of potent EP1 antagonists exemplified by 4c, 4f, and 4j, which were shown to reduce pathological intravesical pressure in rats when administered at 1 mg/kg iv. (C) 2017 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2017.07.055
• 作为产物：
  描述：

  2-amino-6-chloropyrazolo[1,5-a]pyridine 在 正丁基锂 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.5h， 生成 6-chloro-2-(pyrrolidin-1-yl)-7-(trimethylsilyl)pyrazolo[1,5-a]pyridine
  参考文献：
  名称：

  Discovery of novel pyrazolo[1,5-a]pyridine-based EP1 receptor antagonists by scaffold hopping: Design, synthesis, and structure-activity relationships

  摘要：

  A scaffold-hopping strategy towards a new pyrazolo[1,5-a]pyridine based core using molecular hybridization of two structurally distinct EP1 antagonists, followed by structure-activity relationship guided optimization, resulted in the identification of potent EP1 antagonists exemplified by 4c, 4f, and 4j, which were shown to reduce pathological intravesical pressure in rats when administered at 1 mg/kg iv. (C) 2017 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2017.07.055

文献信息

• PYRAZOLOPYRIDINE DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
  申请人：Seto Shigeki

  公开号：US20130331378A1

  公开（公告）日：2013-12-12

  A pyrazolopyridine derivative represented by the following formula (I) or a pharmacologically acceptable salt thereof exhibits a strong EP 1 receptor antagonistic effect. Thus, the derivative or the pharmacologically acceptable salt is useful as a therapeutic agent for lower urinary tract symptoms (LUTS), particularly, overactive bladder syndrome (OABs), or a prophylactic agent therefor and furthermore, is also useful in the treatment, prevention, or suppression of various pathological conditions in which the EP 1 receptor is involved, such as inflammatory disease, pain disease, osteoporosis, and cancer. [A is a benzene ring or the like, Y 1 is C 1-6 alkylene, R 1 is —C(═O)—OZ 1 or the like, Z 1 is H or the like, R 2 is a branched C 3-6 alkyl group or the like, R 3 is H or the like, R 4 is a hydrogen atom or the like, and R 5 is a hydrogen atom or the like].

  以下式(I)所表示的吡唑吡啶衍生物或其药学上可接受的盐，表现出强烈的EP1受体拮抗作用。因此，该衍生物或药学上可接受的盐可用作下尿路症状（LUTS），特别是过度活跃膀胱综合症（OABs）的治疗剂或预防剂，此外，它还可用于治疗、预防或抑制EP1受体参与的各种病理情况，如炎症性疾病、疼痛疾病、骨质疏松症和癌症。其中，A为苯环或类似物，Y1为C1-6烷基，R1为-C（═O）-OZ1或类似物，Z1为H或类似物，R2为支链C3-6烷基或类似物，R3为H或类似物，R4为氢原子或类似物，R5为氢原子或类似物。
• EP2669285
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery of novel pyrazolo[1,5-a]pyridine-based EP1 receptor antagonists by scaffold hopping: Design, synthesis, and structure-activity relationships
  作者：Yosuke Nishigaya、Kentaro Umei、Yoshifumi Saito、Hiroyuki Watanabe、Tatsuhiro Kondo、Atsushi Kondo、Naohiro Kawamura、Kazuya Tatani、Yasushi Kohno、Nobuyuki Tanaka、Shigeki Seto

  DOI：10.1016/j.bmcl.2017.07.055

  日期：2017.9

  A scaffold-hopping strategy towards a new pyrazolo[1,5-a]pyridine based core using molecular hybridization of two structurally distinct EP1 antagonists, followed by structure-activity relationship guided optimization, resulted in the identification of potent EP1 antagonists exemplified by 4c, 4f, and 4j, which were shown to reduce pathological intravesical pressure in rats when administered at 1 mg/kg iv. (C) 2017 Published by Elsevier Ltd.